GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Evolutionary Genomics FNAM · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2022

Revenue

—

FY2014FY2022

Net income

−$1.9m

FY2014FY2022

Free cash flow

−$640,950

FY2014FY2022

Shareholders' equity

−$1.6m

FY2014FY2022

Income statement

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue——$12,500$122,686$114,814$32,690$221,582$262,924$348,031
Research and development$417,450$1.2m$1.8m$472,613$473,992$791,060$719,900$416,160$115,725
Operating income−$2.0m−$2.9m−$2.9m−$774,825−$836,799−$1.3m−$1.1m−$722,858−$24,503
Net income−$1.9m−$2.8m−$1.7m−$793,140−$1.1m−$539,617−$1.2m−$286,000−$27,139
Diluted earnings per share-0.29-0.48-0.29-0.13-0.26-0.09-0.20-0.05-0.21

Balance sheet

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$2.4m$2.9m$4.0m$4.2m$4.4m$5.4m$6.4m$3.2m$1.4m
Cash and short-term investments$577,066$214,009$215,836$87,135$159,606$1.2m$2.1m$261,521$729,277
Total liabilities$3.9m$7.3m$5.8m$4.6m$4.0m$4.0m$4.6m$253,752$13,672
Debt$3.7m$3.7m$2.2m——————
Shareholders' equity−$1.6m−$4.4m−$1.8m−$333,725$403,587$1.4m$1.8m$2.9m−$13,672
Shares outstanding7m6m6m6m4m6m6m6m0m

Cash flow

Fiscal years

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$640,947−$1.6m−$2.3m−$625,980−$748,837−$1.2m−$1.1m−$590,044−$25,803
Capital spending−$3—−$3———−$103,195−$103,195−$164
Free cash flow−$640,950−$1.6m−$2.3m−$625,980−$748,837−$1.2m−$1.2m−$693,239−$25,967
Dividends paid——−$269,379−$269,379−$242,367−$242,366−$196.5m——

Latest quarters

By quarter end

Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021Sept 2021Jun 2021Mar 2021
Operating income−$412,245−$545,681−$531,432−$524,944−$668,079−$1.1m−$553,707−$513,850
Net income−$254,766−$545,277−$530,355−$524,707−$667,844−$1.1m−$553,701−$513,742
Diluted earnings per share-0.04-0.08-0.08-0.08-0.11-0.18-0.09-0.09
Total assets$2.4m$2.7m$3.1m$3.5m$2.9m$3.6m$3.2m$3.6m
Cash and short-term investments$577,066$765,550$897,779$1.0m$214,009$605,508$588$97,558
Debt$3.7m$3.7m$3.7m$3.7m$3.7m$3.7m$2.3m$2.3m
Shareholders' equity−$5.6m−$5.2m−$4.8m−$4.3m−$4.4m−$3.8m−$2.8m−$2.3m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income37.5%9.1%64.2%
Net income34.6%29.1%60.5%

Valuation history

At each fiscal year end

FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013
Price to earnings-0.6-0.4-0.4-1.1-0.1-0.2-0.2-0.6-0.6-0.1
Price to sales——49.76.90.93.51.10.60.1—

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return0%-100%-36%-1%85%-33%500%25%-53%40%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 60.8826-to-1 reverse split · 19 Oct 2015

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.